We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Samus Therapeutics

News List

Samus Therapeutics Launches PU-AD Clinical Program in Alzheimer's Disease americanpharmaceuticalreview
July 25, 2019
Samus Therapeutics announced the initiation of its clinical program for PU-AD, an oral, brain permeable inhibitor of epichaperomes in Alzheimer's Disease (AD) following clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug
Samus Therapeutics Launches PU-AD Clinical Program in Alzheimer's Disease americanpharmaceuticalreview
July 24, 2019
Samus Therapeutics announced the initiation of its clinical program for PU-AD, an oral, brain permeable inhibitor of epichaperomes in Alzheimer's Disease (AD) following clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug